Health Stock on the Rise
This stock could be a major success story in 2021.
Here's why.
Brian Lenz, insider at ADMA Biologics
Brian Lenz Insider Alerts

Get notified the next time Brian Lenz buys or sells ADMA Biologics stock. Enter your email address below to get our daily insider buying and selling report.

Brian Lenz Insider Information

Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer.  Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team.  In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.

Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.

Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.

Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

Mr. Lenz is the finance committee co-chairperson for BioNJ.  He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.

Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include:  Best Growth Manager, Financier of the Year, Public Company and Capital Success.

What is Brian Lenz's net worth?

The estimated net worth of Brian Lenz is at least $46,605.90 as of February 11th, 2020. Mr. Lenz owns 32,142 shares of ADMA Biologics stock worth more than $46,606 as of November 30th. This net worth evaluation does not reflect any other investments that Mr. Lenz may own. Learn More.

How do I contact Brian Lenz?

The corporate mailing address for Mr. Lenz and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]

Has Brian Lenz been buying or selling shares of ADMA Biologics?

During the past quarter, Brian Lenz has bought $30,000.00 in ADMA Biologics stock. Most recently, on Monday, October 25th, Brian Lenz bought 30,000 shares of ADMA Biologics stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $30,000.00.

Who are ADMA Biologics' active insiders?

ADMA Biologics' insider roster includes Adam Grossman (CEO), Young Kwon (Director), and Brian Lenz (CFO).

Are insiders buying or selling shares of ADMA Biologics?

During the last year, ADMA Biologics insiders bought shares 3 times. They purchased a total of 380,000 shares worth more than $380,000.00. During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 2,341,949 shares worth more than $3,015,016.48. The most recent insider tranaction occured on October, 25th when Director Young Kwon bought 100,000 shares worth more than $100,000.00. Insiders at ADMA Biologics own 8.7 % of the company.

Information on this page was last updated on 10/25/2021.

Brian Lenz Insider Trading History at ADMA Biologics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2021Buy30,000$1.00$30,000.00View SEC Filing Icon  
8/11/2020Buy4,000$2.97$11,880.00View SEC Filing Icon  
2/11/2020Buy7,142$3.50$24,997.0032,142View SEC Filing Icon  
5/17/2019Buy5,000$4.00$20,000.0025,000View SEC Filing Icon  
6/8/2018Buy5,000$4.78$23,900.0020,000View SEC Filing Icon  
11/9/2017Buy6,500$2.15$13,975.0015,000View SEC Filing Icon  
5/3/2016Buy2,500$6.50$16,250.008,500View SEC Filing Icon  
12/2/2015Buy1,000$9.15$9,150.006,000View SEC Filing Icon  
5/14/2014Buy1,000$7.50$7,500.00View SEC Filing Icon  
See Full Table

Brian Lenz Buying and Selling Activity at ADMA Biologics

This chart shows Brian Lenz's buying and selling at ADMA Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ADMA Biologics Company Overview

ADMA Biologics logo
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Ramsey, NJ.
Read More

Today's Range

Now: $1.45
Low: $1.41
High: $1.47

50 Day Range

MA: $1.31
Low: $1.09
High: $1.66

2 Week Range

Now: $1.45
Low: $1.01
High: $3.11


1,869,259 shs

Average Volume

2,675,476 shs

Market Capitalization

$283.92 million

P/E Ratio


Dividend Yield



Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity